Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.
作者： Nikolaos Tzoumas , Tariq E. Farrah , Neeraj Dhaun , David J. Webb
DOI: 10.1111/BPH.14920
关键词:
摘要: … Few other pharmaceutical agents have had a history as serendipitous as the class of PDE type 5 … With a growing body of evidence supporting the clinically established safety profile and …
ed.ac.uk
sci-hub.se 参考文章(147)
Irwin Goldstein, Tom F. Lue, Harin Padma-Nathan, Raymond C. Rosen, William D. Steers, Pierre A. Wicker, Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. The New England Journal of Medicine. ,vol. 338, pp. 1397- 1404 ,(1998) , 10.1056/NEJM199805143382001
Carmine Gazzaruso, Sebastiano B. Solerte, Arturo Pujia, Adriana Coppola, Monia Vezzoli, Fabrizio Salvucci, Cinzia Valenti, Andrea Giustina, Adriana Garzaniti, Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. Journal of the American College of Cardiology. ,vol. 51, pp. 2040- 2044 ,(2008) , 10.1016/J.JACC.2007.10.069
F. Giuliano, G. Jackson, F. Montorsi, A. Martin-Morales, P. Raillard, Safety of Sildenafil Citrate: Review of 67 Double-Blind Placebo-Controlled Trials and the Postmarketing Safety Database International Journal of Clinical Practice. ,vol. 64, pp. 240- 255 ,(2009) , 10.1111/J.1742-1241.2009.02254.X
Ulka B. Campbell, Alexander M. Walker, Michael Gaffney, Kenneth R. Petronis, Dana Creanga, Sheila Quinn, Barbara E.K. Klein, Alan M. Laties, Michael Lewis, Ira D. Sharlip, Francesca Kolitsopoulos, Brian J. Klee, Jingping Mo, Robert F. Reynolds, Acute Nonarteritic Anterior Ischemic Optic Neuropathy and Exposure to Phosphodiesterase Type 5 Inhibitors The Journal of Sexual Medicine. ,vol. 12, pp. 139- 151 ,(2015) , 10.1111/JSM.12726
Andrew J Wardle, Matthew J Seager, Richard Wardle, Robert MR Tulloh, J Simon R Gibbs, Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database of Systematic Reviews. ,vol. 2016, ,(2016) , 10.1002/14651858.CD011205.PUB2
Javier Inserte, David Garcia-Dorado, The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism British Journal of Pharmacology. ,vol. 172, pp. 1996- 2009 ,(2015) , 10.1111/BPH.12959
Jae‐Seung Paick, Tai Y. Ahn, Hyung K. Choi, Woo‐Sik Chung, Je J. Kim, Sae C. Kim, Sae W. Kim, Sung W. Lee, Kweon S. Min, Ki H. Moon, Jong K. Park, Kwangsung Park, Nam C. Park, Jun‐Kyu Suh, Dae Y. Yang, Hyung‐Gi Jung, ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Safety of Mirodenafil, A New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction The Journal of Sexual Medicine. ,vol. 5, pp. 2672- 2680 ,(2008) , 10.1111/J.1743-6109.2008.00945.X
Run Wang, Arthur L. Burnett, Warren H. Heller, Kenji Omori, Jun Kotera, Kohei Kikkawa, Shiyin Yee, Wesley W. Day, Karen DiDonato, Craig A. Peterson, Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. The Journal of Sexual Medicine. ,vol. 9, pp. 2122- 2129 ,(2012) , 10.1111/J.1743-6109.2012.02822.X
Giorgio Pomara, Girolamo Morelli, Salvatore Pomara, Stefano Taddei, Lorenzo Ghiadoni, Nicola Dinelli, Fabrizio Travaglini, Mauro Dicuio, Nicola Mondaini, Antonio Salvetti, Cesare Selli, Cardiovascular Parameter Changes in Patients With Erectile Dysfunction Using Pde‐5 Inhibitors: A Study With Sildenafil and Vardenafil Journal of Andrology. ,vol. 25, pp. 625- 629 ,(2004) , 10.1002/J.1939-4640.2004.TB02833.X
Fadi N. Salloum, Yuko Takenoshita, Ramzi A. Ockaili, Vladimir P. Daoud, Eric Chou, Kazu-ichi Yoshida, Rakesh C. Kukreja, Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbits Journal of Molecular and Cellular Cardiology. ,vol. 42, pp. 453- 458 ,(2007) , 10.1016/J.YJMCC.2006.10.015